Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.

Current opinion in molecular therapeutics - 1 Feb 2001

Lycke N

Abstract excerpt

A novel immunomodulating gene-fusion protein, CTA1-DD, has been developed which combines the ADP-ribosylating ability of cholera toxin (CT) with a dimer of an Ig-binding fragment, D, of Staphylococcus aureus protein A. The CTA1-DD adjuvant is non-toxic and greatly augmented T-cell-dependent and T-cell-independent responses to soluble admixed antigens after systemic as well as mucosal immunizations. CTL and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antibody Formation
Share to Antigen-Presenting Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cholera Toxin

Share to Immunity, Mucosal

Share to Poly(ADP-ribose) Polymerases

Share to Staphylococcal Protein A

Share to Vaccines

Source

Identifiers

PMID: 11249730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.PMID 11249730Read ↗

The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability.Semantic proximity Read ↗

Cholera Toxin Subunit B as Adjuvant––An Accelerator in Protective Immunity and a Break in AutoimmunitySemantic proximity Read ↗

Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cellsSemantic proximity Read ↗

Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity.Semantic proximity Read ↗

A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens.Semantic proximity Read ↗

Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.Semantic proximity Read ↗

A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.Semantic proximity Read ↗

Protection against Group A Streptococcus by Immunization with J8–Diphtheria Toxoid: Contribution of J8‐ and Diphtheria Toxoid–Specific Antibodies to ProtectionSemantic proximity Read ↗

Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model.Semantic proximity Read ↗

DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotypeSemantic proximity Read ↗

Reactivation of pre-existing T cell memory by a LADS-TT vaccine induces potent anti-tumor immunity in cervical and colon carcinoma modelsSemantic proximity Read ↗

Allergy Vaccines Using a Mycobacterium-Secreted Antigen, Ag85B, and an IL-4 Antagonist.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.